NASDAQ:ONTX - Onconova Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.93 -0.12 (-2.96 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$4.05
Today's Range$3.76 - $4.00
52-Week Range$3.53 - $39.97
Volume34,500 shs
Average Volume102,397 shs
Market Capitalization$24.85 million
P/E Ratio-0.10
Dividend YieldN/A
Beta1.14
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONTX
Previous Symbol
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio2.82
Quick Ratio2.82

Price-To-Earnings

Trailing P/E Ratio-0.10
Forward P/E Ratio-0.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$790,000.00
Price / Sales28.21
Cash FlowN/A
Price / CashN/A
Book Value($15.11) per share
Price / Book-0.26

Profitability

EPS (Most Recent Fiscal Year)($40.16)
Net Income$-24,090,000.00
Net Margins-1,610.44%
Return on Equity-965.58%
Return on Assets-130.46%

Miscellaneous

Employees25
Outstanding Shares5,670,000
Market Cap$24.85 million
OptionableNot Optionable

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics's stock reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) announced its earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.78) by $0.16. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.87 million. Onconova Therapeutics had a negative net margin of 1,610.44% and a negative return on equity of 965.58%. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

2 equities research analysts have issued 12-month price targets for Onconova Therapeutics' stock. Their forecasts range from $16.00 to $25.00. On average, they anticipate Onconova Therapeutics' stock price to reach $20.50 in the next year. This suggests a possible upside of 421.6% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.

What is the consensus analysts' recommendation for Onconova Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (11/17/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $25 from $3, accounting for the 1:15 reverse split and the following factors: (1) adjustment to base year; (2) adjustment to fully diluted share count; and (3) adjusting our projected launch years for IV rigosertib in high-risk MDS from 2020 to 2021, and 2021 to 2022 for the U.S. and ex-U.S. markets, respectively. Our clinical NPV model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (9/27/2018)
  • 3. Maxim Group analysts commented, "Onconova reported 2Q18 with a net loss of $4.3M and ended the period with $29.5M in cash, runway into 2H19." (8/14/2018)

Has Onconova Therapeutics been receiving favorable news coverage?

News stories about ONTX stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Onconova Therapeutics earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the next several days.

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Ramesh Kumar, Co-Founder, CEO & Director (Age 62)
  • Dr. Steven M. Fruchtman, Chief Medical Officer & Pres (Age 67)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 49)

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Tyndall Capital Partners L P (14.40%), EcoR1 Capital LLC (8.82%), Point72 Asset Management L.P. (4.27%), Kepos Capital LP (3.53%), Kepos Capital LP (3.53%) and Renaissance Technologies LLC (0.99%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin, Michael B Hoffman and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Which major investors are selling Onconova Therapeutics stock?

ONTX stock was sold by a variety of institutional investors in the last quarter, including Tyndall Capital Partners L P, EcoR1 Capital LLC, Point72 Asset Management L.P., Kepos Capital LP, Kepos Capital LP and Renaissance Technologies LLC. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $3.93.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $24.85 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($40.16) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is http://www.onconova.com.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel